<DOC>
	<DOCNO>NCT00005813</DOCNO>
	<brief_summary>RATIONALE : Bispecific antibodies plus white blood cell may able locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness combine bispecific antibody white blood cell treat patient recurrent refractory glioblastoma multiforme .</brief_summary>
	<brief_title>Bispecific Antibody Plus White Blood Cells Treating Patients With Recurrent Refractory Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Assess safety tolerability bispecific antibody MDX447 activate monocyte patient recurrent refractory glioblastoma multiforme . - Determine response , time tumor progression , overall survival patient treat regimen . OUTLINE : This dose escalation study . Patients undergo maximal surgical debulking tumor time reservoir placement . Within 2-4 week surgery , patient receive one treatment intratumoral bispecific antibody MDX447 activate monocyte . Stable respond patient may receive second treatment 1 month later . Cohorts 1 3 patient receive escalate dos bispecific antibody MDX447 activate monocyte maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 patient experience dose limit toxicity . PROJECTED ACCRUAL : A total 13 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven glioblastoma multiforme evidence epidermal growth factor receptor ( EGFR ) expression tumor cell surface No astrocytoma , anaplastic astrocytoma , oligodendroglioma No infratentorial multifocal tumor Recurrence progression follow least one prior therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Greater 2 month Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin great 10 g/dL Hepatic : Bilirubin great 2.0 mg/dL ALT , AST , alkaline phosphatase great 2.5 time upper limit normal ( ULN ) Renal : Creatinine great 2.0 time ULN Other : Not pregnant nursing Fertile patient must use effective contraception No medical psychiatric illness would preclude study No concurrent malignancy except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week since nitrosoureas ) Endocrine therapy : Concurrent steroid therapy allow Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>